Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT03456063
Registration number
NCT03456063
Ethics application status
Date submitted
5/03/2018
Date registered
7/03/2018
Date last updated
31/07/2024
Titles & IDs
Public title
A Study of Neoadjuvant Atezolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Patients With Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer (IMpower030)
Query!
Scientific title
A Phase III, Double-Blinded, Multicenter, Randomized Study Evaluating the Efficacy and Safety of Neoadjuvant Treatment With Atezolizumab or Placebo in Combination With Platinum-Based Chemotherapy in Patients With Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer
Query!
Secondary ID [1]
0
0
GO40241
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Non-Small-Cell Lung
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Lung - Non small cell
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody
Treatment: Drugs - Placebo Comparator
Treatment: Drugs - Nab-paclitaxel
Treatment: Drugs - Pemetrexed
Treatment: Drugs - Carboplatin
Treatment: Drugs - Cisplatin
Treatment: Drugs - Gemcitabine
Experimental: Arm A: Atezolizumab + platinum-based chemotherapy - Neoadjuvant treatment will consist of 4 cycles; atezolizumab + platinum-based chemotherapy
Platinum-based chemotherapy may include:
* carboplatin + pemetrexed
* carboplatin + nab-paclitaxel
* cisplatin + pemetrexed
* cisplatin + gemcitabine
Post-operative adjuvant treatment will consist of 16-cycles of atezolizumab
Placebo comparator: Arm B: Placebo + platinum-based chemotherapy - Neoadjuvant treatment will consist of 4 cycles; placebo + platinum-based chemotherapy
Platinum-based chemotherapy may include:
* carboplatin + pemetrexed
* carboplatin + nab-paclitaxel
* cisplatin + pemetrexed
* cisplatin + gemcitabine
Participants will receive best supportive care and monitoring after surgery
Treatment: Drugs: Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody
Atezolizumab will be administered as intravenous (IV) infusion at a dose of 1200 milligrams (mg) on Day 1 of each 21-day cycle (every 3 weeks) for 4 cycles during the neoadjuvant treatment phase
Atezolizumab will be administered as IV infusion at a dose of 1200 milligrams (mg) every 3 weeks for 16 cycles during the post-operative adjuvant phase
Treatment: Drugs: Placebo Comparator
Placebo will be administered as IV infusion at a dose of 1200 milligrams (mg) on Day 1 of each 21-day cycle for 4 cycles during the neoadjuvant treatment phase
Treatment: Drugs: Nab-paclitaxel
Nab-paclitaxel 100 mg/m\^2 will be administered intravenously on Days 1, 8, and 15 of each 21 day cycle for 4 cycles during the neoadjuvant treatment phase
Treatment: Drugs: Pemetrexed
Pemetrexed 500 mg/m\^2 will be administered intravenously on Day 1 of each 21-day cycle for 4 cycles during the neoadjuvant treatment phase
Treatment: Drugs: Carboplatin
Carboplatin initial target AUC of 6 mg/mL/min will be administered intravenously on Day 1 of each 21-day cycle for 4 cycles during the neoadjuvant treatment phase
Treatment: Drugs: Cisplatin
Cisplatin 75 mg/m\^2 will be administered intravenously on Day 1 of each 21-day cycle for 4 cycles during the neoadjuvant treatment phase
Treatment: Drugs: Gemcitabine
Gemcitabine 1250 mg/m\^2 will be administered intravenously on Day 1 and 8 of each 21-day cycle for 4 cycles during the neoadjuvant treatment phase
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Independent Review Facility (IRF)-Assessed Event Free Survival (EFS)
Query!
Assessment method [1]
0
0
IRF-assessed EFS is defined as the time from randomization to the first documented disease progression per RECIST v1.1 that precludes surgery, local or distant disease recurrence, or death from any cause, whichever occurs first.
Query!
Timepoint [1]
0
0
Up to approximately 96 months
Query!
Secondary outcome [1]
0
0
Pathological Complete Response (pCR)
Query!
Assessment method [1]
0
0
pCR is defined as the absence of any viable primary tumor cells at the time of surgical resection in the primary tumor and all sampled lymph nodes as assessed by central and local pathology laboratory.
Query!
Timepoint [1]
0
0
At time of surgery
Query!
Secondary outcome [2]
0
0
Major Pathological Response (MPR)
Query!
Assessment method [2]
0
0
MPR is defined as = 10% residual viable tumor cells at the time of surgical resection in the primary tumor, as assessed by central and local pathology laboratory.
Query!
Timepoint [2]
0
0
At time of surgery
Query!
Secondary outcome [3]
0
0
Objective Response (OR)
Query!
Assessment method [3]
0
0
Objective response is defined as a complete response or partial response, as determined by the investigator according to RECIST v1.1
Query!
Timepoint [3]
0
0
Prior to surgery, up to approximately 84 days
Query!
Secondary outcome [4]
0
0
Overall Survival (OS)
Query!
Assessment method [4]
0
0
OS is defined as the time from randomization to death from any cause during the course of the study.
Query!
Timepoint [4]
0
0
Up to approximately 96 months
Query!
Secondary outcome [5]
0
0
Investigator-Assessed EFS
Query!
Assessment method [5]
0
0
EFS is defined as the time from randomization to the first documented disease progression per RECIST v1.1 that precludes surgery, local or distant disease recurrence, as assessed by the investigator; or death from any cause, whichever occurs first.
Query!
Timepoint [5]
0
0
Up to approximately 96 months
Query!
Secondary outcome [6]
0
0
Disease-Free Survival (DFS)
Query!
Assessment method [6]
0
0
DFS is defined as the time from the first date of no disease to local or distant recurrence (including occurrence of new primary NSCLC) or death due to any cause, whichever occurs first, as determined by the investigator during the adjuvant treatment and observation follow-up
Query!
Timepoint [6]
0
0
Up to approximately 96 months
Query!
Secondary outcome [7]
0
0
2-Year and 3-Year OS
Query!
Assessment method [7]
0
0
The 2-year and 3-year OS rate is defined as the probability that a participant will be alive 2 years and 3 years after randomization, respectively.
Query!
Timepoint [7]
0
0
Up to approximately 96 months
Query!
Secondary outcome [8]
0
0
2-Year and 3-Year Independent Review Facility-Assessed EFS
Query!
Assessment method [8]
0
0
EFS is defined as the probability that a participant will be event-free 2 years and 3 years after randomization, respectively, as assessed by the Independent Review Facility.
Query!
Timepoint [8]
0
0
Up to approximately 96 months
Query!
Secondary outcome [9]
0
0
2-Year and 3-Year Investigator-Assessed EFS
Query!
Assessment method [9]
0
0
EFS is defined as the probability that a participant will be event-free 2 years and 3 years after randomization, respectively, as assessed by the Investigator.
Query!
Timepoint [9]
0
0
Up to approximately 96 months
Query!
Secondary outcome [10]
0
0
Change from baseline in HRQoL scores
Query!
Assessment method [10]
0
0
Change from baseline in HRQoL scores as assessed through use of the two-item GHS/HRQoL subscale (Questions 29 and 30) of the EORTC QLQ-C30 at each assessment time point during the study through the completion of adjuvant treatment and observation follow-up assessments
Query!
Timepoint [10]
0
0
Up to approximately 96 months
Query!
Secondary outcome [11]
0
0
Percentage of Participants With Adverse Events (AEs)
Query!
Assessment method [11]
0
0
Query!
Timepoint [11]
0
0
Up to approximately 96 months
Query!
Secondary outcome [12]
0
0
Number and Severity of Surgical Related Adverse Events
Query!
Assessment method [12]
0
0
Query!
Timepoint [12]
0
0
Up to approximately 96 months
Query!
Secondary outcome [13]
0
0
Number of Surgical Delays
Query!
Assessment method [13]
0
0
Number of surgical delays.
Query!
Timepoint [13]
0
0
Up to approximately 96 months
Query!
Secondary outcome [14]
0
0
Length of Surgical Delays
Query!
Assessment method [14]
0
0
Length of surgical delays.
Query!
Timepoint [14]
0
0
Up to approximately 96 months
Query!
Secondary outcome [15]
0
0
Number of Operative and Post-Operative Complications
Query!
Assessment method [15]
0
0
Number of operative and post-operative complications.
Query!
Timepoint [15]
0
0
Up to approximately 96 months
Query!
Secondary outcome [16]
0
0
Reasons for Surgical Cancellations
Query!
Assessment method [16]
0
0
Reasons for surgical cancellations.
Query!
Timepoint [16]
0
0
Up to approximately 96 months
Query!
Secondary outcome [17]
0
0
Minimum Observed Serum Atezolizumab Concentration (Cmin)
Query!
Assessment method [17]
0
0
Cmin is the minimum (or trough) concentration that a study drug achieves in the body.
Query!
Timepoint [17]
0
0
Pre-dose on Day 1 of Cycles 1 and 3 (each cylce is 21 days) for Neoadjuvant Treatment; pre-dose on Day 1 of Cycles 5, 7, 9, 11 and 19 (each cycle is 21 days) for Arm A; at treatment or observation follow-up discontinuation (up to approximately 96 months)
Query!
Secondary outcome [18]
0
0
Maximum Observed Serum Atezolizumab Concentration (Cmax)
Query!
Assessment method [18]
0
0
Cmax is the maximum (or peak) concentration that a study drug achieves in the body.
Query!
Timepoint [18]
0
0
Pre-dose on Day 1 of Cycles 1 and 3 for Neoadjuvant Treatment; Pre-dose on Day 1 of Cycles 5, 7, 9, 11 and 19 for Arm A. Each cycle is 21 days; at treatment or observation follow-up discontinuation (up to approximately 96 months)
Query!
Secondary outcome [19]
0
0
Percentage of Participants With Anti-Drug Antibody (ADA) to Atezolizumab
Query!
Assessment method [19]
0
0
Query!
Timepoint [19]
0
0
Pre-dose on Day 1 of Cycles 1 and 3 for Neoadjuvant Treatment; Pre-dose on Day 1 of Cycles 5, 7, 9, 11 and 19 for Arm A. Each cycle is 21 days; at treatment or observation follow-up discontinuation (up to approximately 96 months)
Query!
Eligibility
Key inclusion criteria
Inclusion criteria:
* Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
* Histologically or cytologically confirmed, resectable Stage II, IIIA, or Select IIIB (T3N2 only) NSCLC of squamous or non-squamous histology. Staging should be based on the 8th edition of the AJCC/UICC staging system
* Evaluation by an attending thoracic surgeon to confirm eligibility for an R0 resection with curative intent
* Adequate pulmonary and cardiac function to undergo surgical resection
* Measurable disease as defined by RECIST v1.1
* Adequate hematologic and end organ function
* Negative HIV test at screening
* Negative for active HBV and HCV at screening
* Adequate tissue for PD-L1 IHC assessment
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
Exclusion criteria:
* NSCLC with histology of large cell neuroendocrine carcinoma or sarcomatoid carcinoma
* Mixed NSCLC and small cell lung cancer histology
* Any prior therapy for lung cancer
* Malignancies other than NSCLC within 5 years prior to randomization, with the exception of those with a negligible risk of metastasis or death treated expected curative outcome
* Non-squamous NSCLC histology with activating ALK and EGFR mutation
* Pregnant or lactating women
* History of autoimmune disease
* History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, or evidence of active of active pneumonitis on screening chest Computed Tomography (CT) scan
* Prior treatment with cluster of differentiation 137 (CD137) agonist or immune checkpoint blockade therapies, anti-programmed-death-1 (anti-PD-1), and anti-PD-L1 therapeutic antibody
* Severe infection within 4 weeks prior to randomization
* Significant history of cardiovascular disease
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Active, not recruiting
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
24/04/2018
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
19/01/2025
Query!
Actual
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
453
Query!
Recruitment in Australia
Recruitment state(s)
NSW,VIC
Query!
Recruitment hospital [1]
0
0
St George Hospital; Cancer Care Centre - Kogarah
Query!
Recruitment hospital [2]
0
0
Box Hill Hospital; Oncology - Box Hill
Query!
Recruitment hospital [3]
0
0
Peter MacCallum Cancer Center - North Melbourne
Query!
Recruitment postcode(s) [1]
0
0
2217 - Kogarah
Query!
Recruitment postcode(s) [2]
0
0
3128 - Box Hill
Query!
Recruitment postcode(s) [3]
0
0
3051 - North Melbourne
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Arizona
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
California
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Colorado
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
District of Columbia
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Illinois
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Maine
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Maryland
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Michigan
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Minnesota
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Missouri
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Nebraska
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
New York
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
North Carolina
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Pennsylvania
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Tennessee
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
Texas
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
Virginia
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
Washington
Query!
Country [19]
0
0
Austria
Query!
State/province [19]
0
0
Linz
Query!
Country [20]
0
0
Austria
Query!
State/province [20]
0
0
Wien
Query!
Country [21]
0
0
Brazil
Query!
State/province [21]
0
0
MG
Query!
Country [22]
0
0
Brazil
Query!
State/province [22]
0
0
RS
Query!
Country [23]
0
0
Brazil
Query!
State/province [23]
0
0
SP
Query!
Country [24]
0
0
China
Query!
State/province [24]
0
0
Shanghai
Query!
Country [25]
0
0
France
Query!
State/province [25]
0
0
Angers
Query!
Country [26]
0
0
France
Query!
State/province [26]
0
0
Lyon
Query!
Country [27]
0
0
France
Query!
State/province [27]
0
0
Saint Quentin
Query!
Country [28]
0
0
France
Query!
State/province [28]
0
0
Saint-Mande
Query!
Country [29]
0
0
France
Query!
State/province [29]
0
0
Strasbourg
Query!
Country [30]
0
0
France
Query!
State/province [30]
0
0
Toulon
Query!
Country [31]
0
0
Germany
Query!
State/province [31]
0
0
Freiburg
Query!
Country [32]
0
0
Germany
Query!
State/province [32]
0
0
Gauting
Query!
Country [33]
0
0
Germany
Query!
State/province [33]
0
0
Gerlingen
Query!
Country [34]
0
0
Germany
Query!
State/province [34]
0
0
Großhansdorf
Query!
Country [35]
0
0
Germany
Query!
State/province [35]
0
0
Halle
Query!
Country [36]
0
0
Germany
Query!
State/province [36]
0
0
Oldenburg
Query!
Country [37]
0
0
Germany
Query!
State/province [37]
0
0
Regensburg
Query!
Country [38]
0
0
Germany
Query!
State/province [38]
0
0
Würzburg
Query!
Country [39]
0
0
Hungary
Query!
State/province [39]
0
0
Budapest
Query!
Country [40]
0
0
Israel
Query!
State/province [40]
0
0
Beer Sheva
Query!
Country [41]
0
0
Israel
Query!
State/province [41]
0
0
Haifa
Query!
Country [42]
0
0
Israel
Query!
State/province [42]
0
0
Kfar-Saba
Query!
Country [43]
0
0
Israel
Query!
State/province [43]
0
0
Tel Aviv
Query!
Country [44]
0
0
Italy
Query!
State/province [44]
0
0
Lazio
Query!
Country [45]
0
0
Italy
Query!
State/province [45]
0
0
Lombardia
Query!
Country [46]
0
0
Italy
Query!
State/province [46]
0
0
Toscana
Query!
Country [47]
0
0
Italy
Query!
State/province [47]
0
0
Veneto
Query!
Country [48]
0
0
Japan
Query!
State/province [48]
0
0
Aichi
Query!
Country [49]
0
0
Japan
Query!
State/province [49]
0
0
Fukuoka
Query!
Country [50]
0
0
Japan
Query!
State/province [50]
0
0
Hiroshima
Query!
Country [51]
0
0
Japan
Query!
State/province [51]
0
0
Hyogo
Query!
Country [52]
0
0
Japan
Query!
State/province [52]
0
0
Kyoto
Query!
Country [53]
0
0
Japan
Query!
State/province [53]
0
0
Miyagi
Query!
Country [54]
0
0
Japan
Query!
State/province [54]
0
0
Okayama
Query!
Country [55]
0
0
Japan
Query!
State/province [55]
0
0
Osaka
Query!
Country [56]
0
0
Japan
Query!
State/province [56]
0
0
Tokyo
Query!
Country [57]
0
0
Korea, Republic of
Query!
State/province [57]
0
0
Busan
Query!
Country [58]
0
0
Korea, Republic of
Query!
State/province [58]
0
0
Gyeonggi-do
Query!
Country [59]
0
0
Korea, Republic of
Query!
State/province [59]
0
0
Seoul
Query!
Country [60]
0
0
Poland
Query!
State/province [60]
0
0
Gdansk
Query!
Country [61]
0
0
Poland
Query!
State/province [61]
0
0
Kraków
Query!
Country [62]
0
0
Poland
Query!
State/province [62]
0
0
Warszawa
Query!
Country [63]
0
0
Russian Federation
Query!
State/province [63]
0
0
Moskovskaja Oblast
Query!
Country [64]
0
0
Russian Federation
Query!
State/province [64]
0
0
Sankt Petersburg
Query!
Country [65]
0
0
Serbia
Query!
State/province [65]
0
0
Belgrade
Query!
Country [66]
0
0
Slovenia
Query!
State/province [66]
0
0
Golnik
Query!
Country [67]
0
0
South Africa
Query!
State/province [67]
0
0
Johannesburg
Query!
Country [68]
0
0
South Africa
Query!
State/province [68]
0
0
Pretoria
Query!
Country [69]
0
0
Spain
Query!
State/province [69]
0
0
Barcelona
Query!
Country [70]
0
0
Spain
Query!
State/province [70]
0
0
Islas Baleares
Query!
Country [71]
0
0
Spain
Query!
State/province [71]
0
0
Navarra
Query!
Country [72]
0
0
Spain
Query!
State/province [72]
0
0
Vizcaya
Query!
Country [73]
0
0
Spain
Query!
State/province [73]
0
0
Madrid
Query!
Country [74]
0
0
Spain
Query!
State/province [74]
0
0
Malaga
Query!
Country [75]
0
0
Spain
Query!
State/province [75]
0
0
Sevilla
Query!
Country [76]
0
0
Spain
Query!
State/province [76]
0
0
Valencia
Query!
Country [77]
0
0
Sweden
Query!
State/province [77]
0
0
Linköping
Query!
Country [78]
0
0
Sweden
Query!
State/province [78]
0
0
Lund
Query!
Country [79]
0
0
Sweden
Query!
State/province [79]
0
0
Stockholm
Query!
Country [80]
0
0
Sweden
Query!
State/province [80]
0
0
Uppsala
Query!
Country [81]
0
0
Switzerland
Query!
State/province [81]
0
0
Lausanne
Query!
Country [82]
0
0
Switzerland
Query!
State/province [82]
0
0
Zürich
Query!
Country [83]
0
0
Taiwan
Query!
State/province [83]
0
0
Kaohsiung
Query!
Country [84]
0
0
Taiwan
Query!
State/province [84]
0
0
Taipei
Query!
Country [85]
0
0
Taiwan
Query!
State/province [85]
0
0
Xitun Dist.
Query!
Country [86]
0
0
Thailand
Query!
State/province [86]
0
0
Bangkok
Query!
Country [87]
0
0
Thailand
Query!
State/province [87]
0
0
ChiangMai
Query!
Country [88]
0
0
Ukraine
Query!
State/province [88]
0
0
Dnipropetrovsk
Query!
Country [89]
0
0
United Kingdom
Query!
State/province [89]
0
0
Birmingham
Query!
Country [90]
0
0
United Kingdom
Query!
State/province [90]
0
0
Leeds
Query!
Country [91]
0
0
United Kingdom
Query!
State/province [91]
0
0
Liverpool
Query!
Country [92]
0
0
United Kingdom
Query!
State/province [92]
0
0
London
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
Hoffmann-La Roche
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This is a randomized, double-blinded study designed to evaluate the efficacy, safety, pharmacokinetics, and immunogenicity of neoadjuvant treatment with atezolizumab (MPDL3280A) or placebo in combination with platinum-based chemotherapy in participants with resectable Stage II, IIIA, or select IIIB non-small cell lung cancer (NSCLC) followed by open-label adjuvant/postoperative atezolizumab or best supportive care and monitoring.
Query!
Trial website
https://clinicaltrials.gov/study/NCT03456063
Query!
Trial related presentations / publications
Romero Roman A, Campo-Canaveral de la Cruz JL, Macia I, Escobar Campuzano I, Figueroa Almanzar S, Delgado Roel M, Galvez Munoz C, Garcia Fontan EM, Muguruza Trueba I, Romero Vielva L, Cano Garcia JR, Martinez Tellez E, Partida Gonzalez C, Jimenez Lopez MF, Jimenez Maestre U, Mongil Poce R, Sanchez Lorente D, Alvarez Kindelan A, Provencio Pulla M. Outcomes of surgical resection after neoadjuvant chemoimmunotherapy in locally advanced stage IIIA non-small-cell lung cancer. Eur J Cardiothorac Surg. 2021 Jul 14;60(1):81-88. doi: 10.1093/ejcts/ezab007.
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Clinical Trials
Query!
Address
0
0
Hoffmann-La Roche
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results not provided in
https://clinicaltrials.gov/study/NCT03456063
Download to PDF